{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:07Z","timestamp":1792788427066,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001543","name":"Neurological Foundation of New Zealand","doi-asserted-by":"publisher","award":["1951 MS"],"award-info":[{"award-number":["1951 MS"]}],"id":[{"id":"10.13039\/501100001543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["21\/034"],"award-info":[{"award-number":["21\/034"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001509","name":"Royal Society Te Ap\u0101rangi","doi-asserted-by":"publisher","award":["22-UOA-049-CSG"],"award-info":[{"award-number":["22-UOA-049-CSG"]}],"id":[{"id":"10.13039\/501100001509","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["1176607"],"award-info":[{"award-number":["1176607"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Te T\u012btoki Mataora","award":["3729858"],"award-info":[{"award-number":["3729858"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) and multiple system atrophy (MSA) are two distinct \u03b1-synucleinopathies traditionally differentiated through clinical symptoms. Early diagnosis of MSA is problematic, and seed amplification assays (SAAs), such as real-time quaking-induced conversion (RT-QuIC), offer the potential to distinguish these diseases through their underlying \u03b1-synuclein (\u03b1-Syn) pathology and proteoforms. Currently, SAAs provide a binary result, signifying either the presence or absence of \u03b1-Syn seeds. To enhance the diagnostic potential and biological relevance of these assays, there is a pressing need to incorporate quantification and stratification of \u03b1-Syn proteoform-specific aggregation kinetics into current SAA pipelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Optimal RT-QuIC assay conditions for \u03b1-Syn seeds extracted from PD and MSA patient brains were determined, and assay kinetics were assessed for \u03b1-Syn seeds from different pathologically relevant brain regions (medulla, substantia nigra, hippocampus, middle temporal gyrus, and cerebellum). The conformational profiles of disease- and region-specific \u03b1-Syn proteoforms were determined by subjecting the amplified reaction products to concentration-dependent proteolytic digestion with proteinase K.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using our protocol, PD and MSA could be accurately delineated using proteoform-specific aggregation kinetics, including \u03b1-Syn aggregation rate, maximum relative fluorescence, the gradient of amplification, and core protofilament size. MSA cases yielded significantly higher values than PD cases across all four kinetic parameters in brain tissues, with the MSA-cerebellar phenotype having higher maximum relative fluorescence than the MSA-Parkinsonian phenotype. Statistical significance was maintained when the data were analysed regionally and when all regions were grouped.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our RT-QuIC protocol and analysis pipeline can distinguish between PD and MSA, and between MSA phenotypes. MSA \u03b1-Syn seeds induce faster propagation and exhibit higher aggregation kinetics than PD \u03b1-Syn, mirroring the biological differences observed in brain tissue. With further validation of these quantitative parameters, we propose that SAAs could advance from a yes\/no diagnostic to a theranostic biomarker that could be utilised in developing therapeutics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40035-025-00469-6","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T23:08:56Z","timestamp":1738883336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Refining \u03b1-synuclein seed amplification assays to distinguish Parkinson\u2019s disease from multiple system atrophy"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-1612","authenticated-orcid":false,"given":"James A.","family":"Wiseman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton P.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L. M.","family":"Faull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda M.","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birger Victor","family":"Dieriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"1","key":"469_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"TF Outeiro","year":"2019","unstructured":"Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, et al. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019;14(1):5.","journal-title":"Mol Neurodegener"},{"issue":"Pt B","key":"469_CR2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.nbd.2017.07.018","volume":"109","author":"C Peng","year":"2018","unstructured":"Peng C, Gathagan RJ, Lee VM. Distinct \u03b1-Synuclein strains and implications for heterogeneity among \u03b1-Synucleinopathies. Neurobiol Dis. 2018;109(Pt B):209\u201318.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"469_CR3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s40478-021-01242-2","volume":"9","author":"EW Hass","year":"2021","unstructured":"Hass EW, Sorrentino ZA, Xia Y, Lloyd GM, Trojanowski JQ, Prokop S, et al. Disease-, region- and cell type specific diversity of \u03b1-synuclein carboxy terminal truncations in synucleinopathies. Acta Neuropathol Commun. 2021;9(1):146.","journal-title":"Acta Neuropathol Commun"},{"issue":"7","key":"469_CR4","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3390\/biom11070931","volume":"11","author":"SO Hoppe","year":"2021","unstructured":"Hoppe SO, Uzuno\u011flu G, Nussbaum-Krammer C. \u03b1-Synuclein strains: does amyloid conformation explain the heterogeneity of synucleinopathies? Biomolecules. 2021;11(7):931.","journal-title":"Biomolecules"},{"key":"469_CR5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1749-6632.2000.tb06900.x","volume":"920","author":"MG Spillantini","year":"2000","unstructured":"Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson\u2019s disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci. 2000;920:16\u201327.","journal-title":"Ann N Y Acad Sci"},{"issue":"7706","key":"469_CR6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-018-0104-4","volume":"557","author":"C Peng","year":"2018","unstructured":"Peng C, Gathagan RJ, Covell DJ, Medellin C, Stieber A, Robinson JL, et al. Cellular milieu imparts distinct pathological \u03b1-synuclein strains in \u03b1-synucleinopathies. Nature. 2018;557(7706):558\u201363.","journal-title":"Nature"},{"key":"469_CR7","doi-asserted-by":"crossref","first-page":"666585","DOI":"10.3389\/fchem.2021.666585","volume":"9","author":"N Bisi","year":"2021","unstructured":"Bisi N, Feni L, Peqini K, P\u00e9rez-Pe\u00f1a H, Ongeri S, Pieraccini S, et al. \u03b1-Synuclein: an all-inclusive trip around its structure, influencing factors and applied techniques. Front Chem. 2021;9:666585.","journal-title":"Front Chem"},{"issue":"10","key":"469_CR8","doi-asserted-by":"crossref","first-page":"e2012171118","DOI":"10.1073\/pnas.2012171118","volume":"118","author":"P Kumari","year":"2021","unstructured":"Kumari P, Ghosh D, Vanas A, Fleischmann Y, Wiegand T, Jeschke G, et al. Structural insights into \u03b1-synuclein monomer-fibril interactions. Proc Natl Acad Sci U S A. 2021;118(10):e2012171118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"469_CR9","doi-asserted-by":"crossref","unstructured":"Wiseman JA, Reddy K, Dieriks BV. From onset to advancement: the temporal spectrum of \u03b1-synuclein in synucleinopathies. Ageing Res Rev. 2024:102640.","DOI":"10.1016\/j.arr.2024.102640"},{"issue":"7825","key":"469_CR10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41586-020-2317-6","volume":"585","author":"M Schweighauser","year":"2020","unstructured":"Schweighauser M, Shi Y, Tarutani A, Kametani F, Murzin AG, Ghetti B, et al. Structures of \u03b1-synuclein filaments from multiple system atrophy. Nature. 2020;585(7825):464\u20139.","journal-title":"Nature"},{"issue":"1","key":"469_CR11","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1038\/s41467-019-13564-w","volume":"10","author":"T Stroh\u00e4ker","year":"2019","unstructured":"Stroh\u00e4ker T, Jung BC, Liou SH, Fernandez CO, Riedel D, Becker S, et al. Structural heterogeneity of \u03b1-synuclein fibrils amplified from patient brain extracts. Nat Commun. 2019;10(1):5535.","journal-title":"Nat Commun"},{"issue":"7933","key":"469_CR12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-05319-3","volume":"610","author":"Y Yang","year":"2022","unstructured":"Yang Y, Shi Y, Schweighauser M, Zhang X, Kotecha A, Murzin AG, et al. Structures of \u03b1-synuclein filaments from human brains with Lewy pathology. Nature. 2022;610(7933):791\u20135.","journal-title":"Nature"},{"issue":"Suppl 1","key":"469_CR13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/jnc.13595","volume":"139","author":"W Peelaerts","year":"2016","unstructured":"Peelaerts W, Baekelandt V. \u0251-Synuclein strains and the variable pathologies of synucleinopathies. J Neurochem. 2016;139(Suppl 1):256\u201374.","journal-title":"J Neurochem"},{"issue":"1","key":"469_CR14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00401-023-02663-0","volume":"147","author":"GM Bentivenga","year":"2024","unstructured":"Bentivenga GM, Mammana A, Baiardi S, Rossi M, Ticca A, Magliocchetti F, et al. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathol. 2024;147(1):18.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"469_CR15","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.29005","volume":"37","author":"GK Wenning","year":"2022","unstructured":"Wenning GK, Stankovic I, Vignatelli L, Fanciulli A, Calandra-Buonaura G, Seppi K, et al. The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord. 2022;37(6):1131\u201348.","journal-title":"Mov Disord"},{"issue":"12","key":"469_CR16","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30(12):1591\u2013601.","journal-title":"Mov Disord"},{"issue":"2","key":"469_CR17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1474-4422(23)00512-4","volume":"23","author":"JA Obeso","year":"2024","unstructured":"Obeso JA, Calabressi P. Parkinson\u2019s disease is a recognisable and useful diagnostic entity. Lancet Neurol. 2024;23(2):133\u20134.","journal-title":"Lancet Neurol"},{"issue":"3","key":"469_CR18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(20)30477-4","volume":"20","author":"P Hermann","year":"2021","unstructured":"Hermann P, Appleby B, Brandel JP, Caughey B, Collins S, Geschwind MD, et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol. 2021;20(3):235\u201346.","journal-title":"Lancet Neurol"},{"issue":"6","key":"469_CR19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","volume":"117","author":"TG Beach","year":"2009","unstructured":"Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009;117(6):613\u201334.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"469_CR20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24(2):197\u2013211.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"469_CR21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(21)00036-3","volume":"20","author":"I Zerr","year":"2021","unstructured":"Zerr I. RT-QuIC for detection of prodromal \u03b1-synucleinopathies. Lancet Neurol. 2021;20(3):165\u20136.","journal-title":"Lancet Neurol"},{"issue":"5","key":"469_CR22","first-page":"1268","volume":"28","author":"LM Chahine","year":"2022","unstructured":"Chahine LM. Prodromal \u03b1-synucleinopathies. Continuum (Minneap Minn). 2022;28(5):1268\u201380.","journal-title":"Continuum (Minneap Minn)"},{"issue":"1","key":"469_CR23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40035-022-00283-4","volume":"11","author":"I Martinez-Valbuena","year":"2022","unstructured":"Martinez-Valbuena I, Visanji NP, Kim A, Lau HHC, So RWL, Alshimemeri S, et al. Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy. Transl Neurodegener. 2022;11(1):7.","journal-title":"Transl Neurodegener"},{"issue":"7794","key":"469_CR24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, et al. Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature. 2020;578(7794):273\u20137.","journal-title":"Nature"},{"issue":"5","key":"469_CR25","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/mds.28976","volume":"37","author":"M Luan","year":"2022","unstructured":"Luan M, Sun Y, Chen J, Jiang Y, Li F, Wei L, et al. Diagnostic value of salivary real-time quaking-induced conversion in Parkinson\u2019s disease and multiple system atrophy. Mov Disord. 2022;37(5):1059\u201363.","journal-title":"Mov Disord"},{"key":"469_CR26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40035-019-0164-x","volume":"8","author":"CMG De Luca","year":"2019","unstructured":"De Luca CMG, Elia AE, Portaleone SM, Cazzaniga FA, Rossi M, Bistaffa E, et al. Efficient RT-QuIC seeding activity for \u03b1-synuclein in olfactory mucosa samples of patients with Parkinson\u2019s disease and multiple system atrophy. Transl Neurodegener. 2019;8:24.","journal-title":"Transl Neurodegener"},{"issue":"6","key":"469_CR27","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","volume":"139","author":"A Van der Perren","year":"2020","unstructured":"Van der Perren A, Gelders G, Fenyi A, Bousset L, Brito F, Peelaerts W, et al. The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of Parkinson\u2019s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol. 2020;139(6):977\u20131000.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"469_CR28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40035-022-00311-3","volume":"11","author":"M Bongianni","year":"2022","unstructured":"Bongianni M, Catalan M, Perra D, Fontana E, Janes F, Bertolotti C, et al. Olfactory swab sampling optimization for \u03b1-synuclein aggregate detection in patients with Parkinson\u2019s disease. Transl Neurodegener. 2022;11(1):37.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"469_CR29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41531-021-00242-2","volume":"7","author":"A Kuzkina","year":"2021","unstructured":"Kuzkina A, Bargar C, Schmitt D, R\u00f6\u00dfle J, Wang W, Schubert AL, et al. Diagnostic value of skin RT-QuIC in Parkinson\u2019s disease: a two-laboratory study. NPJ Parkinsons Dis. 2021;7(1):99.","journal-title":"NPJ Parkinsons Dis"},{"issue":"10","key":"469_CR30","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1515\/cclm-2023-1472","volume":"62","author":"A Mammana","year":"2024","unstructured":"Mammana A, Baiardi S, Rossi M, Quadalti C, Ticca A, Magliocchetti F, et al. Improving protocols for \u03b1-synuclein seed amplification assays: analysis of preanalytical and analytical variables and identification of candidate parameters for seed quantification. Clin Chem Lab Med. 2024;62(10):2001\u201310.","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"469_CR31","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1021\/acs.jpcb.2c08326","volume":"127","author":"J Vaneyck","year":"2023","unstructured":"Vaneyck J, Yousif TA, Segers-Nolten I, Blum C, Claessens MMAE. Quantitative seed amplification assay: a proof-of-principle study. J Phys Chem B. 2023;127(8):1735\u201343.","journal-title":"J Phys Chem B"},{"issue":"5","key":"469_CR32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/v8050140","volume":"8","author":"CD Orr\u00fa","year":"2016","unstructured":"Orr\u00fa CD, Hughson AG, Groveman BR, Campbell KJ, Anson KJ, Manca M, et al. Factors that improve RT-QuIC detection of prion seeding activity. Viruses. 2016;8(5):140.","journal-title":"Viruses"},{"key":"469_CR33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40035-019-0181-9","volume":"9","author":"N Candelise","year":"2020","unstructured":"Candelise N, Schmitz M, Th\u00fcne K, Cramm M, Rabano A, Zafar S, et al. Effect of the micro-environment on \u03b1-synuclein conversion and implication in seeded conversion assays. Transl Neurodegener. 2020;9:5.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"469_CR34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/cells10010139","volume":"10","author":"A Fenyi","year":"2021","unstructured":"Fenyi A, Duyckaerts C, Bousset L, Braak H, Del Tredici K, Melki R, et al. Seeding propensity and characteristics of pathogenic \u03b1Syn assemblies in formalin-fixed human tissue from the enteric nervous system, olfactory bulb, and brainstem in cases staged for Parkinson\u2019s disease. Cells. 2021;10(1):139.","journal-title":"Cells"},{"issue":"11","key":"469_CR35","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/nprot.2016.120","volume":"11","author":"M Schmitz","year":"2016","unstructured":"Schmitz M, Cramm M, Llorens F, M\u00fcller-Cramm D, Collins S, Atarashi R, et al. The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases. Nat Protoc. 2016;11(11):2233\u201342.","journal-title":"Nat Protoc"},{"issue":"3","key":"469_CR36","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1074\/jbc.RA118.004471","volume":"294","author":"TR Yamasaki","year":"2019","unstructured":"Yamasaki TR, Holmes BB, Furman JL, Dhavale DD, Su BW, Song ES, et al. Parkinson\u2019s disease and multiple system atrophy have distinct \u03b1-synuclein seed characteristics. J Biol Chem. 2019;294(3):1045\u201358.","journal-title":"J Biol Chem"},{"issue":"1","key":"469_CR37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/cimb46010040","volume":"46","author":"T Arakawa","year":"2024","unstructured":"Arakawa T, Niikura T, Kita Y, Akuta T. Sodium dodecyl sulfate analogs as a potential molecular biology reagent. Curr Issues Mol Biol. 2024;46(1):621\u201333.","journal-title":"Curr Issues Mol Biol"},{"issue":"1","key":"469_CR38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40035-024-00456-3","volume":"13","author":"JA Wiseman","year":"2024","unstructured":"Wiseman JA, Fu Y, Faull RLM, Turner CP, Curtis MA, Halliday GM, Dieriks BV. N-terminus \u03b1-synuclein detection reveals new and more diverse aggregate morphologies in multiple system atrophy and Parkinson\u2019s disease. Transl Neurodegener. 2024;13(1):67.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"469_CR39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40035-023-00342-4","volume":"12","author":"M Schmitz","year":"2023","unstructured":"Schmitz M, Candelise N, Canaslan S, Altmeppen HC, Matschke J, Glatzel M, et al. \u03b1-Synuclein conformers reveal link to clinical heterogeneity of \u03b1-synucleinopathies. Transl Neurodegener. 2023;12(1):12.","journal-title":"Transl Neurodegener"},{"key":"469_CR40","doi-asserted-by":"crossref","unstructured":"Perra D, Bongianni M, Novi G, Janes F, Bessi V, Capaldi S, et al. Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies. Brain Commun. 2021;3(2):fcab045.","DOI":"10.1093\/braincomms\/fcab045"},{"issue":"1","key":"469_CR41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40035-023-00345-1","volume":"12","author":"S Duan","year":"2023","unstructured":"Duan S, Yang J, Cui Z, Li J, Zheng H, Zhao T, et al. Seed amplification assay of nasal swab extracts for accurate and non-invasive molecular diagnosis of neurodegenerative diseases. Transl Neurodegener. 2023;12(1):13.","journal-title":"Transl Neurodegener"},{"issue":"6","key":"469_CR42","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mds.29340","volume":"38","author":"A Kuzkina","year":"2023","unstructured":"Kuzkina A, Panzer C, Seger A, Schmitt D, R\u00f6\u00dfle J, Schreglmann SR, et al. Dermal real-time quaking-induced conversion is a sensitive marker to confirm isolated rapid eye movement sleep behavior disorder as an early \u03b1-synucleinopathy. Mov Disord. 2023;38(6):1077\u201382.","journal-title":"Mov Disord"},{"issue":"1","key":"469_CR43","first-page":"1","volume":"78","author":"Z Wang","year":"2020","unstructured":"Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M, et al. Skin \u03b1-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol. 2020;78(1):1\u201311.","journal-title":"JAMA Neurol"},{"issue":"18","key":"469_CR44","doi-asserted-by":"crossref","first-page":"e1944","DOI":"10.1212\/WNL.0000000000207147","volume":"100","author":"A Iranzo","year":"2023","unstructured":"Iranzo A, Mammana A, Mu\u00f1oz-Lopetegi A, Dellavalle S, May\u00e0 G, Rossi M, et al. Misfolded \u03b1-synuclein assessment in the skin and CSF by RT-QuIC in isolated REM sleep behavior disorder. Neurology. 2023;100(18):e1944\u201354.","journal-title":"Neurology"},{"issue":"1","key":"469_CR45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41531-023-00473-5","volume":"9","author":"R Liguori","year":"2023","unstructured":"Liguori R, Donadio V, Wang Z, Incensi A, Rizzo G, Antelmi E, et al. A comparative blind study between skin biopsy and seed amplification assay to disclose pathological \u03b1-synuclein in RBD. NPJ Parkinsons Dis. 2023;9(1):34.","journal-title":"NPJ Parkinsons Dis"},{"issue":"6","key":"469_CR46","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno SI, Imamichi-Tatano Y, et al. Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med. 2023;29(6):1448\u201355.","journal-title":"Nat Med"},{"key":"469_CR47","doi-asserted-by":"crossref","first-page":"806122","DOI":"10.3389\/fnhum.2022.806122","volume":"16","author":"Q Ren","year":"2022","unstructured":"Ren Q, Wang Y, Xia X, Zhang J, Zhao C, Meng X. Differentiation of Parkinson\u2019s disease and Parkinsonism predominant multiple system atrophy in early stage by morphometrics in susceptibility weighted imaging. Front Hum Neurosci. 2022;16:806122.","journal-title":"Front Hum Neurosci"},{"issue":"10","key":"469_CR48","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/mds.27485","volume":"33","author":"TG Beach","year":"2018","unstructured":"Beach TG, Adler CH. Importance of low diagnostic Accuracy for early Parkinson\u2019s disease. Mov Disord. 2018;33(10):1551\u20134.","journal-title":"Mov Disord"},{"issue":"15","key":"469_CR49","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/mds.22826","volume":"24","author":"Y Osaki","year":"2009","unstructured":"Osaki Y, Ben-Shlomo Y, Lees AJ, Wenning GK, Quinn NP. A validation exercise on the new consensus criteria for multiple system atrophy. Mov Disord. 2009;24(15):2272\u20136.","journal-title":"Mov Disord"},{"issue":"6","key":"469_CR50","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","volume":"86","author":"G Rizzo","year":"2016","unstructured":"Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86(6):566\u201376.","journal-title":"Neurology"},{"issue":"2","key":"469_CR51","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awab431","volume":"145","author":"I Poggiolini","year":"2022","unstructured":"Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A, Querejeta-Coma A, et al. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain. 2022;145(2):584\u201395.","journal-title":"Brain"},{"issue":"4","key":"469_CR52","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","volume":"18","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio L, Pritzkow S, Shahnawaz M, Farris CM, Soto C. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nat Protoc. 2023;18(4):1179\u201396.","journal-title":"Nat Protoc"},{"issue":"3","key":"469_CR53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ana.25824","volume":"88","author":"W Singer","year":"2020","unstructured":"Singer W, Schmeichel AM, Shahnawaz M, Schmelzer JD, Boeve BF, Sletten DM, et al. Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from lewy body synucleinopathies. Ann Neurol. 2020;88(3):503\u201312.","journal-title":"Ann Neurol"},{"key":"469_CR54","doi-asserted-by":"crossref","unstructured":"Chlebowicz J, Russ W, Chen D, Vega A, Vernino S, White CL 3rd, Rizo J, Joachi et al. Saturation mutagenesis of \u03b1-synuclein reveals monomer fold that modulates aggregation. Sci Adv. 2023;9(43):eadh3457.","DOI":"10.1126\/sciadv.adh3457"},{"issue":"35","key":"469_CR55","doi-asserted-by":"crossref","first-page":"e2023487118","DOI":"10.1073\/pnas.2023487118","volume":"118","author":"RP McGlinchey","year":"2021","unstructured":"McGlinchey RP, Ni X, Shadish JA, Jiang J, Lee JC. The N terminus of \u03b1-synuclein dictates fibril formation. Proc Natl Acad Sci U S A. 2021;118(35):e2023487118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"28","key":"469_CR56","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1021\/bi027363r","volume":"42","author":"IV Murray","year":"2003","unstructured":"Murray IV, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, Ischiropoulos H, et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry. 2003;42(28):8530\u201340.","journal-title":"Biochemistry"},{"issue":"49","key":"469_CR57","doi-asserted-by":"crossref","first-page":"18914","DOI":"10.1074\/jbc.RA118.005603","volume":"293","author":"ZA Sorrentino","year":"2018","unstructured":"Sorrentino ZA, Vijayaraghavan N, Gorion KM, Riffe CJ, Strang KH, Caldwell J, et al. Physiological C-terminal truncation of \u03b1-synuclein potentiates the prion-like formation of pathological inclusions. J Biol Chem. 2018;293(49):18914\u201332.","journal-title":"J Biol Chem"},{"issue":"14","key":"469_CR58","doi-asserted-by":"crossref","first-page":"9843","DOI":"10.1074\/jbc.274.14.9843","volume":"274","author":"L Narhi","year":"1999","unstructured":"Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, et al. Both familial Parkinson\u2019s disease mutations accelerate alpha-synuclein aggregation. J Biol Chem. 1999;274(14):9843\u20136.","journal-title":"J Biol Chem"},{"key":"469_CR59","doi-asserted-by":"crossref","first-page":"1177556","DOI":"10.3389\/fmolb.2023.1177556","volume":"10","author":"H Gram","year":"2023","unstructured":"Gram H, Theologidis V, Boesen T, Jensen PH. Sarkosyl differentially solubilizes patient-derived alpha-synuclein fibril strains. Front Mol Biosci. 2023;10:1177556.","journal-title":"Front Mol Biosci"},{"issue":"9","key":"469_CR60","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/mds.25115","volume":"27","author":"IN Petrovic","year":"2012","unstructured":"Petrovic IN, Ling H, Asi Y, Ahmed Z, Kukkle PL, Hazrati LN, et al. Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord. 2012;27(9):1186\u201390.","journal-title":"Mov Disord"},{"issue":"2","key":"469_CR61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00401-005-1029-1","volume":"110","author":"K Wakabayashi","year":"2005","unstructured":"Wakabayashi K, Mori F, Nishie M, Oyama Y, Kurihara A, Yoshimoto M, et al. An autopsy case of early (\u201cminimal change\u201d) olivopontocerebellar atrophy (multiple system atrophy-cerebellar). Acta Neuropathol. 2005;110(2):185\u201390.","journal-title":"Acta Neuropathol"},{"issue":"Pt 1","key":"469_CR62","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/brain\/awp282","volume":"133","author":"J Tong","year":"2010","unstructured":"Tong J, Wong H, Guttman M, Ang LC, Forno LS, Shimadzu M, et al. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson\u2019s disease and progressive supranuclear palsy: a comparative investigation. Brain. 2010;133(Pt 1):172\u201388.","journal-title":"Brain"},{"issue":"38","key":"469_CR63","doi-asserted-by":"crossref","first-page":"E5308","DOI":"10.1073\/pnas.1514475112","volume":"112","author":"SB Prusiner","year":"2015","unstructured":"Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, et al. Evidence for \u03b1-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A. 2015;112(38):E5308\u201317.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"469_CR64","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/ncomms3575","volume":"4","author":"L Bousset","year":"2013","unstructured":"Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B, et al. Structural and functional characterization of two alpha-synuclein strains. Nat Commun. 2013;4:2575.","journal-title":"Nat Commun"},{"issue":"3","key":"469_CR65","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/13506129.2018.1517736","volume":"25","author":"A Sidhu","year":"2018","unstructured":"Sidhu A, Vaneyck J, Blum C, Segers-Nolten I, Subramaniam V. Polymorph-specific distribution of binding sites determines thioflavin-T fluorescence intensity in \u03b1-synuclein fibrils. Amyloid. 2018;25(3):189\u201396.","journal-title":"Amyloid"},{"issue":"1","key":"469_CR66","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.str.2022.11.013","volume":"31","author":"Y Fan","year":"2023","unstructured":"Fan Y, Sun Y, Yu W, Tao Y, Xia W, Liu Y, et al. Conformational change of \u03b1-synuclein fibrils in cerebrospinal fluid from different clinical phases of Parkinson\u2019s disease. Structure. 2023;31(1):78-87.e5.","journal-title":"Structure"},{"issue":"1","key":"469_CR67","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/19336896.2019.1704612","volume":"14","author":"VV Kushnirov","year":"2020","unstructured":"Kushnirov VV, Dergalev AA, Alexandrov AI. Proteinase K resistant cores of prions and amyloids. Prion. 2020;14(1):11\u20139.","journal-title":"Prion"},{"issue":"5","key":"469_CR68","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mdc3.13710","volume":"10","author":"A Grossauer","year":"2023","unstructured":"Grossauer A, Hemicker G, Krismer F, Peball M, Djamshidian A, Poewe W, et al. \u03b1-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid-A systematic review and meta-analysis. Mov Disord Clin Pract. 2023;10(5):737\u201347.","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"469_CR69","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13024-021-00491-y","volume":"16","author":"C Bargar","year":"2021","unstructured":"Bargar C, De Luca CMG, Devigili G, Elia AE, Cilia R, Portaleone SM, et al. Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories. Mol Neurodegener. 2021;16(1):82.","journal-title":"Mol Neurodegener"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-025-00469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-025-00469-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-025-00469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T10:47:39Z","timestamp":1739789259000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-025-00469-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1186\/s40035-025-00469-6","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human post-mortem brain tissue used in this study was received from (1) the Sydney Brain Bank, and (2) the Neurological Foundation Human Brain Bank (New Zealand). All brain tissue was donated with written informed consent from donors and their families prior to brain removal and all protocols were approved by the University of Sydney Human Research Ethics Committee (2019\/491) and the University of Auckland Human Participants Ethics Committee (Ref: 011654). All experiments were conducted in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial or non-financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}